New Azithromycin Form Launched In China

27 November 1995

Beijing UniPharm Laboratories and Beijing Taiyang Pharmaceutical Industries have launched a new crystalline form of azithromycin, the active component of Pfizer's Zithromax antibiotic, in China. The drug is marketed under the trade name Tailite.

BUL claims, and China's Drug Evaluation Committee agrees, that its crystalline form does not infringe on Pfizer's patents for its dihydrate crystalline version, as BUL's drug has different thermal chemical properties, X-ray diffraction pattern and infrared spectrum. Pfizer was granted pharmaceutical administrative protection earlier this year in China. Beijing Taiyang manufactures Tailite for BUL, which launched the drug on November 8.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight